Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update
Provided By GlobeNewswire
Last update: Nov 18, 2024
Phase 2 CLOVER-WaM pivotal study data selected for oral presentation at 66th Annual American Society of Hematology Meeting and Exposition
Read more at globenewswire.com
